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Abstract: Despite considerable improvements in the treatment of cardiovascular diseases, heart
failure (HF) still represents one of the leading causes of death worldwide. Poor prognosis is mostly
due to the limited regenerative capacity of the adult human heart, which ultimately leads to left
ventricular dysfunction. As a consequence, heart transplantation is virtually the only alternative for
many patients. Therefore, novel regenerative approaches are extremely needed, and several attempts
have been performed to improve HF patients’ clinical conditions by promoting the replacement of
the lost cardiomyocytes and by activating cardiac repair. In particular, cell-based therapies have been
shown to possess a great potential for cardiac regeneration. Different cell types have been extensively
tested in clinical trials, demonstrating consistent safety results. However, heterogeneous efficacy data
have been reported, probably because precise end-points still need to be clearly defined. Moreover,
the principal mechanism responsible for these beneficial effects seems to be the paracrine release of
antiapoptotic and immunomodulatory molecules from the injected cells. This review covers past and
state-of-the-art strategies in cell-based heart regeneration, highlighting the advantages, challenges,
and limitations of each approach.
Keywords: heart dysfunction; heart failure; cardiac regeneration; stem cells; cell therapy; cardiac
clinical trials; translational medicine
1. Introduction
Cardiovascular diseases (CVDs) represent one of the leading causes of death in the world.
An estimated 17.7 million people died from CVD each year, corresponding approximately to 31%
of all global deaths [1]. Acute myocardial infarction (AMI), a life-threatening condition resulting
from a complete interruption of the blood flow to the heart [2], is considered one of the major
components of CVDs, including nearly 580,000 new coronary attacks and 210,000 recurrent attacks
every year in the United States [3]. Nonetheless, AMI induces a characteristic pattern of ultrastructural,
cellular, molecular, and metabolic alterations, which leads to irreversible cardiac damage, ultimately
culminating in heart failure [4]. In the past 10 years, despite improvements and innovations in CVDs
treatment, the number of patients diagnosed with HF increased by 23% [5], thus representing a
challenging issue for both the scientific community and the health care systems. The estimated costs
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associated with HF management have globally reached 108 billion dollars per year [6]. These statistics
provide a perfect picture of the magnitude of the impact of chronic heart diseases (CHDs) on society,
and the development of novel therapies is urgently warranted.
In the human heart, adult cardiomyocytes (CMs) are able to divide and exhibit spontaneous
turnover [7]. Despite this, heart transplantation still represents the gold standard for the treatment
of end-stage HF, because it is characterized by an extremely high late-survival rate and by a
significant improvement of the patients’ quality of life [8]. Unfortunately, the limited number of
heart donors, which is not sufficient to cover the increasing organ demand, and the mandatory
transplant-associated lifelong immunosuppressant therapy reduce the feasibility of this therapeutic
approach, which could not be applied on a large scale [9]. Moreover, many HF patients are ineligible
for heart transplantation because of concomitant comorbidities, and they remain without possible
medical, surgical, or interventional treatment options [10]. These are the main reasons why alternative
regenerative approaches are extremely needed, and great effort has been directed accordingly by the
scientific community for the past 25 years.
The primary therapeutic target of all these innovative strategies is to reduce the myocardial
scar by generating new functional cardiac tissue and activating endogenous cardiac-associated
mechanisms of repair. The first approach that was attempted was to replace dead cardiomyocytes by
the exogenous administration of progenitor cells. Several different cell sources have been employed,
ranging from bone marrow stem cells to resident cardiac stem cells [11,12]. More recently, direct
cardiac reprogramming strategies have been proposed to generate cardiomyocytes starting from
terminally committed cells (i.e., dermal fibroblasts), in order to overcome the technical limitations
associated with stem cells [13–15]. Moreover, a direct reprogramming approach could be potentially
directly applied in vivo on the scar tissue, reverting the cardiac myofibroblasts into cardiomyocytes
and restoring the cardiac functionality [16]. However, while several research groups have already
demonstrated its efficacy both in vitro [17–19] and in animal models [16,20,21], several critical issues
still need to be addressed, including the extremely low conversion rate, the incomplete maturation
of the induced-cardiomyocytes, and the safety concerns related to the use of genetic material and
viruses to induce the transdifferentiation process. Therefore, to date, no clinical applications nor
clinical trials have been developed with direct reprogramming approaches [22]. On the contrary,
in the past two decades, almost 100 clinical trials with adult stem cells of different tissue origin have
been performed [23]. However, while no major adverse safety issues have been observed with the
administration of most adult stem cells, the real efficacy of these approaches is still controversial [24].
Indeed, an unbiased comparison of the trial outcomes is challenging, because of the use of stem
cells from different tissue sources, as well as the extreme variability in the protocols and in the patient
populations that were chosen [25]. Nonetheless, in this review, we tried to provide an accurate analysis
of the different cell-based regenerative strategies that have been proposed and developed, illustrating
the pros and cons of each approach, drawing an overall picture of where we are today and where we
are heading.
2. Cell Therapy
2.1. Initial Studies with Committed Cells
The first cell therapy attempt (i.e., injection of exogenous cells) for heart regeneration was
performed with skeletal myoblasts [26]. This approach was conceived mainly because of the high
availability of these cells from autologous sources, their ability to proliferate in vitro and to regenerate
skeletal muscle after an injury, and their somewhat high resistance to ischemic insults. Unfortunately,
once cells were transplanted into the heart, results were unsuccessful, as they differentiated only into
skeletal muscle and not into CMs [27], although some beneficial effects were observed on the infarcted
heart of animal models [28–30]. Nonetheless, a series of clinical studies using skeletal myoblasts
were performed (Table 1) [31–34]. Early results showed a general amelioration in cardiac function,
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especially in left ventricular ejection fraction (LVEF), in regional contractility, and in both viability
and perfusion of the treated area [35,36], although other clinical studies failed to reproduce these
encouraging results [37].
Table 1. Clinical trials with committed cells (skeletal myoblasts) for cardiac regeneration.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Pagani [32] Phase I ICM SI Treated: 5 Not shown
Siminiak [33] Phase I AMI SI Treated: 10 Yes
Menasche [37] MAGIC CHF SI Treated: 97Control: 30 Not shown
Povsic [34] MARVEL-I CHF SI Treated: 15Control: 8 Not shown
ICM: ischemic cardiomyopathy; SI: sub-epicardial injection; AMI: acute myocardial infarction; CHF: chronic
heart failure.
Later, further attempts were made using fetal cardiomyocytes. However, while initial results
engrafting fetal CMs in syngeneic recipients seemed promising, as they showed the formation of
new myocardium in injured hearts [38,39] and functional improvement after small grafts, long-term
studies revealed massive cell death and limited proliferation of the implanted cells, as expected with
differentiated cells [40,41]. Therefore, the use of CMs was abandoned, as it was clear that the number
of cells needed to regenerate the damaged area had to be incredibly higher than the few cells that
survived transplantation. Thus, the scientific community started to look into other cell sources that
would be able to proliferate after injection, thus increasing their number, before differentiating [42,43].
Indeed, as described in the next section, stem cells intrinsically possess the ability to self-renew and
differentiate into different cell types. For this reason, they have soon become the ideal choice for
regenerative heart approaches.
2.2. Stem Cells
As stem cell biology has developed over the past two decades, progenitor cells of different sources
have become available for regenerative medicine, including cardiac repair. Indeed, several types of
stem cells have been investigated, and several therapeutic approaches attempted, as detailed below.
2.2.1. Embryonic Stem Cells
Embryonic Stem Cells (ESCs) have been considered ideal candidates to produce CMs for cardiac
repair due to their pluripotency and self-renewal. However, while they were initially isolated in the
mouse [44] and other species [45–47], they have been available from human sources only relatively
recently, as they were isolated from a human blastocyst and cultured in vitro only in 1998 [48].
Successively, CMs were generated from both mouse and human ESCs using different differentiation
protocols. The first described method is based on the generation of embryoid bodies, which are
spherical cell aggregates formed via self-aggregation of ESCs [49]. The CMs generated from ESCs
expressed specific cardiac genes, such as GATA4, Nkx2.5, troponin I, troponin T, α-myosin heavy
chain, ventricular myosin light chain, and connexin 43 and 45, proteins typical of gap junctions [50].
The efficiency, which was initially low, was successively increased through a co-culture protocol of
ESCs and the endoderm-like cell line, END-2 [51,52], and, successively, by modulating the environment
with growth factors to reproduce the in vivo early stage of embryonic cardiac development [53,54].
The first in vivo experiments conducted on rat [55] and pig [50] models showed that ESC-derived CMs
were able to proliferate, to express cardiac markers, and to form pacemaker cells, coupling electrically
with resident CMs, also after myocardial infarction [56–58]. Actually, in a non-human primate model,
it has been demonstrated that an intramyocardial delivery of 1 billion human ESC-derived CMs gave
re-muscularization of the infarcted zone, despite an incomplete CMs maturation. However, adverse
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arrhythmic complications were observed [59]. A successive study indicated that the re-muscularization
by ESC-derived CMs was able to restore cardiac function after transplantation, as demonstrated by the
increase of the global left ventricular ejection fraction after one and three months [60]. In the meantime,
the first clinical trial on a human patient was performed showing an improved cardiac functional
outcome after three months from the cardiac-committed ESCs implantation [61]. More recently, a small
phase I trial (n = 6) demonstrated the technical feasibility of producing clinical-grade ESC-derived
CMs and their medium-term safety (Table 2) [62].
Overall, while positive results have been reported, the same original concerns about the
employment of ESCs on humans are still actual, especially regarding their tumorigenic potential,
the immune rejection [63], and the ethical issues on cell isolation from blastocysts.
Table 2. Clinical trials with ESCs for cardiac regeneration.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Menasche [61] Case Report HF FS 1 Yes
Menasche [62] Phase I ICM FS Treated: 6 Not shown
HF: heart failure; FS: fibrin scaffold; ICM: ischemic cardiomyopathy.
2.2.2. Adult Stem Cells
Adult stem cells have been isolated from a variety of human tissues. However, their use in cardiac
regeneration is limited to the following sources:
Bone Marrow Stem Cells (BMSCs)
BMSCs are a heterogeneous population of stem cells isolated from the bone marrow that is
often divided into two main subtypes, depending on their surface markers: hematopoietic bone
marrow stem cells (BM-HSCs) characterized by the expression of CD31, CD34, CD45, and CD133, and
mesenchymal bone marrow stem cells (BM-MSCs), which express CD73, CD90, and CD105 [64]. The
isolation procedure of the stem cell population from bone marrow is a well-established protocol based
on density gradient centrifugation. The resulting product is defined as bone marrow mononuclear
cells (BMMNCs), which includes BM-HSCs, BM-MSCs, and committed cells in the various stages of
differentiation. BMMNC represent the first stem cell population employed in clinical trials (Table 3),
although it has been demonstrated that they do not directly contribute to the formation of the
cardiac cell lineage. The TOPCARE-AMI (Transplantation Of Progenitor Cells And Regenerations
Enhancement in Acute Myocardial Infarction) trial was one of the first clinical trials with adult
stem cells, and it was conducted on 20 randomized patients, receiving an intracoronary infusion of
BMMNCs after 4–5 days from an acute myocardial infarction. Results showed a modest increase of
the cardiac function after four months of follow-up in addition to the feasibility and safety of the
intracoronary infusion of BMMNCs [65]. Many other clinical trials employed BMMNCs, including, for
example, the BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial [66], the
REPAIR-AMI (Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial
Infarction) trial [67], the SWISS-AMI (SWiss multicenter Intracoronary Stem cells Study in Acute
Myocardial Infarction) trial [68], or the TIME (Timing In Myocardial infarction Evaluation) trial [69].
The majority of the clinical trials with BMMNCs reported a modest improvement of left ventricular
function and cardiac perfusion by enhanced microvascularization [65,66,68–70]. Even though the
cell population employed was namely the same, there were significant differences among the trials,
regarding the number of cells implanted, the delivery method or the patients’ population. These
differences made difficult a reliable comparison of the trials’ outcome and also the reproducibility.
An example of this aspect is represented by the two versions of the BOOST trial. The former trial
was conducted in 2004 on infarcted patients (n = 60) who received an infusion of BMMNCs. After six
months from the intervention, the treated group showed an increase of 6.7% of the mean global left
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ventricle ejection fraction, compared to an increase of 0.7% of the control group [66]. However, in the
subsequent randomized placebo-controlled, double-blind BOOST-2 trial, they investigated the effects
of a low or a high dose of infused cells and the effects of the γ-irradiation, but they failed to reproduce
the positive effects observed before [71].
Table 3. Clinical trials with BMMNCs for cardiac regeneration.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Hamano [72] Phase I ICM IM Treated: 5 Not shown
Strauer [70] Phase I AMI IC Treated: 10Control: 10 Yes
Assmus [65]
Leistner [73] TOPCARE-AMI AMI IC Treated: 59 Yes
Wollert [66] BOOST AMI IC Treated: 30Control: 30 Yes
Lunde [74] ASTAMI AMI IC Treated: 24Control: 25 Not shown
Schachinger [67] REPAIR-AMI AMI IC Treated: 101Control: 103 Yes
Surder [68]
Suerder [75] SWISS-AMI AMI IC
Treated: 128
Control: 64 No
Wohrle [76] SCAMY AMI IC Treated: 29Control: 13 No
Strauer [77] STAR-heart ICM IC Treated: 191Control: 200 Yes
Traverse [69] The TIMEStudy AMI IC
Treated: 79
Control: 41 No
ICM: ischemic cardiomyopathy; IM: intramyocardial injection; AMI: acute myocardial infarction; IC:
intracoronary infusion.
Since BMMNCs include not only stem cells, but also committed cells, several groups conducted
clinical trials with a purified population of bone marrow stem cells. In particular, HSCs (CD34+
and/or CD133+), representing the most abundant stem cell population in BMMNCs (2–4%), were the
first purified stem cell population to be used in clinical trials (Table 4). Initially, positive results
were obtained by Stamm et al. [78], who described an increase in LVEF and cardiac perfusion six
months after transplant. However, in a second study with a more accurate experimental design,
they did not reproduce the same results [79]. In this regard, it was demonstrated that HSCs are not
able to differentiate into cardiomyocytes once implanted into the heart [80], and that the observed
beneficial effects on patients were a consequence of their angiogenic [72,81,82], rather than their
differentiation, capacity. Moreover, results from other clinical trials did not show any improvement in
cardiac function [69,75,83], highlighting the poor reproducibility of this method, probably due to the
different strategies of cell purification, expansion, and concentration [84].
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Table 4. Clinical trials with BM-HSCs for cardiac regeneration.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Stamm [78] Phase I ICM IM Treated: 35Control: 20 Yes
Tendera [85] REGENT AMI IC Treated: 160Control: 40 No
Povsic [86] RENEW RA IM Treated: 57Control: 55 Not shown
Noiseux [87] IMPACT-CABG ICM IM Treated: 20Control: 20 Not shown
Quyyum [88] PreSERVE-AMI AMI IC Treated: 78Control: 83 Yes
ICM: ischemic cardiomyopathy; IM: intramyocardial injection; AMI: acute myocardial infarction; IC: intracoronary
infusion; RA: refractory angina.
Considering the issues in HSCs manipulation, many groups focused their attention on BM-MSCs,
which were easier to use and standardize due to their capacity to be cultured and expanded with
well-defined procedures [89], including the potential to differentiate into a variety of adult cell types.
Indeed, promising results, characterized by an amelioration of cardiac function and a reduction of
the infarct size, were obtained on rodent and swine models [90–92]. For these reasons, more than 20
clinical trials were conducted with BM-MSCs (Table 5). In general, the results showed improvements
of the cardiac function, demonstrated by an increase of cardiac perfusion or reduction of the infarcted
area, accompanied by signs of angiogenesis and reduced fibrosis and scar formation [93–95]. However,
only a few of these clinical trials presented a well-organized and detailed experimental design and
described a measurable improvement of the cardiac function with specific indicators, such as the
comparison of the LVEF to a correct control group. Most of these trials observed the beneficial effects
at 6 or 12 months of follow-up, while there were no differences between treated and untreated patients
at a longer follow-up. However, the enormous effort spent in these trials strongly increased the
knowledge of BM-MSCs biology and stem cells therapy. For example, the POSEIDON (PercutaneOus
StEm cell Injection Delivery effect On Neomyogenesis) trial demonstrated that BM-MSCs could be
used for allogenic transplant without severe immunological response [93], and that to obtain at
least little improvements in the clinical outcome, it was necessary to infuse at least 70 million cells,
as demonstrated by the SEED-MSC (SafEty and Efficacy of aDult Mesenchymal Stem Cells), C-CURE
Cardiopoietic stem Cell therapy in heart failURE), and MSC-HF (Mesenchymal Stem Cells for Heart
Failure) trials [96–98].
Table 5. Clinical trials with BM-MSCs for cardiac regeneration
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Chen [99] Phase II AMI IC Treated: 34Control: 35 Yes
Chen [100] Phase II AMI IC Treated: 24Control: 24 No
Hare [101] Phase I AMI IV Treated: 39Control: 21 No
Yang [102] Phase I AMI IC Treated: 16 No control
Hare [93] POSEIDON ICM IM Treated: 31 No control
Bartunek [96] C-CURE ICM IM Treated: 32Control: 15 Yes
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Table 5. Cont.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Gao [103] Phase II AMI IC Treated: 21Control: 22 No
Rodrigo [104] Phase I AMI IM Treated: 9Control: 45 No
Karantalis [105] PROMETHEUS ICM IM Treated: 6 No control
Heldman [94] TAC-HFT ICM IM Treated: 22Control: 11 No
Lee [97] SEED-MSC AMI IC Treated: 33Control: 36 Yes
Ascheim [106] Phase II ICM IM Treated: 20Control: 10 No
Chullikana [107] Phase I/II AMI IV Treated: 10Control: 10 No
Perin [108] Phase II ICM IM Treated: 45Control: 15 No
Mathiasen [98] MSC-HF ICM IM Treated: 40Control: 20 Yes
Guijarro [109] MESAMI ICM IM Treated: 10 No control
Xiao [110] - DC IC Treated: 17Control: 20 Yes
Florea [111] TRIDENT ICM IM Treated: 30 No control
Butler [112] Phase II Non-ICM IV Treated: 11Control: 12 No
Bartunek [113] CHART-I ICM IM Treated: 120Control: 151 No
AMI: acute myocardial infarction; IC: intracoronary infusion; IV: intravenous injection; ICM:
ischemic cardiomyopathy; IM: intramyocardial injection; DC: deleted cardiomyopathy; non-ICM:
non-ischemic cardiomyopathy.
Adipose-Derived MSCs (ADSCs)
ADSCs are mesenchymal stem cells derived from adipose tissue, are more abundant than BMSCs,
and have been demonstrated to possess a higher capacity to form colonies than BM-MSCs. Also, they
have shown greater expansion potential and more resistance to senescence following the culture
passages [114]. On the other hand, the surgical procedure for the isolation of the adipose tissue
presents a certain risk of organ injury, sepsis, and pulmonary embolism [115]. The first experiment
of ADSCs cardiac infusion on a rat model of chronic myocardial infarction improved the LVEF,
preventing wall thinning [116], reducing fibrosis, and promoting angiogenesis [117]. On the contrary,
clinical trials in humans showed only modest beneficial effects on cardiac function and on myocardial
perfusion [88,118–121] (Table 6). In particular, a reduction of the infarct size was observed in the
APOLLO trial [118] and improvement of the exercise tolerance was described in the ATHENA I/II
trial [121]. However, no one revealed a significant improvement in the left ventricle function. Thus,
it is still unclear as to what mechanisms are responsible for the effects mediated by ADSCs, also
because there is contradictory evidence on their ability to differentiate into cardiomyocytes [122,123].
Most likely, ADSCs exert paracrine effects promoting angiogenesis [124] and secrete various cytokines
important for tissue regeneration [125,126].
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Table 6. Clinical trials with ADSCs for cardiac regeneration.
Ref. Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Houtgraaf [118] APOLLO AMI IC Treated: 10Control: 4 No
Perin [119] PRECISE ICM IM Treated: 21Control: 6 No
Henry [121] ATHENA I ICM IM Treated: 17Control: 14 No
Kastrup [120] ATHENA II ICM IM Treated: 10 No control
Qayyum [88] MyStromalCell ICM IM Treated: 41Control: 20 Not shown
AMI: acute myocardial infarction; IC: intracoronary infusion; ICM: ischemic cardiomyopathy; IM:
intramyocardial injection.
Umbilical Cord-Derived MSCs (UC-MSCs)
In the last few years, great interest has been directed to stem cells isolated from a different part
of the umbilical cord because of their high capacity of self-renewal and their reduced potential of
forming teratomas [127]. Moreover, their isolation is a simple enzymatic digestion protocol performed
on medical waste, thus avoiding invasive biopsy or ethical concerns. Among them, cells isolated from
the Wharton’s jelly have properties of both ESCs and adult stem cells [128]. Preclinical studies with
human cells showed an increase in cardiac vascularization and attenuated remodeling in rat models
of myocardial infarction [129–131]. Moreover, an increase in cardiac function was also observed in a
swine model [132]. The observed improvements were likely the results of a paracrine effect, rather
than the differentiation in new cardiomyocytes, as demonstrated by the increase of angiogenesis, the
recruitment of endogenous cardiogenic cells, and by the decrease of apoptosis and fibrosis [129–131].
Based on these encouraging results, the use of umbilical cord-derived stem cells was also tested in
humans to develop a possible new clinical application for cardiac regeneration. The main scope of
these trials was first the safety of the allogeneic transplant of the UC-MSCs: interestingly, no severe
adverse effects were observed [133–135]. Then, four clinical trials included a control group in order
to assess a potential therapeutic effect of the UC-MSCs (Table 7). All these trials reported positive
results in terms of LVEF in treated patients as compared to controls at different time points (from 6 to
18 months). Moreover, increases in both exercise tolerance and quality of life were observed [136–138].
These preliminary results, although promising, need to be confirmed in larger and more organized
clinical trials.
Table 7. Clinical trials with UC-MSCs for cardiac regeneration.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Li [134] - ICM IC Treated: 15 No control
Musialek [135] - AMI IC Treated: 10 No control
Fang [133] - ICM IV Treated: 3 No control
Zhao [138] - ICM IM Treated: 30Control: 29 Yes
Gao [137] Phase II AMI IC Treated: 58Control: 58 Yes
Can [139] HUC-HEART ICM IM Treated: 18Control: 4 Not shown
Bartolucci [136] RIMECARD ICM IV Treated: 15Control: 15 Yes
ICM: ischemic cardiomyopathy; IC: intracoronary infusion; AMI: acute myocardial infarction; IV: intravenous
injection; IM: intramyocardial injection.
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Skeletal Muscle-Derived Stem Cells (Satellite Cells)
Satellite cells are the resident stem cells of the skeletal muscle. These mononucleated myogenic
cells proliferate during postnatal growth and their number declines during aging. In the adult skeletal
muscle, satellite cells remain quiescent under the basal lamina of the muscle fiber, but they result
separated from the fiber itself, and they activate after injury in order to repair muscle damage [140].
In the early 1990s, satellite cells were the first adult stem cell population that were tested for cardiac
regeneration in animal models of myocardial injury [141,142]. In particular, the effects of the cardiac
injection of canine satellite cells have been evaluated in terms of cells engraftment and differentiation
into cardiac-like muscle cells. Histological results confirmed that the cardiac environment was sufficient
to induce satellite cells differentiation. However, no functional evaluation has been performed in order
to corroborate the actual cardiac recovery after satellite cells transplantation.
Ten years later, a phase I clinical trial has been conducted to examine the feasibility and safety of
the intramyocardial transplantation of autologous skeletal muscle-derived satellite cells in patients with
non-acute myocardial infarction. Treatment was performed on twelve patients by injecting (100–400)
× 106 cells previously expanded in vitro. Results confirmed that the procedure was safe and feasible.
Moreover, the satellite cells injection was able to improve the LVEF and the viability of the damaged
cardiac tissue (Table 8) [143].
Despite these encouraging results, several critical issues, such as the in vitro expansion procedure
and the disability of the differentiated cells to contract simultaneously with the resident cardiac tissue,
limited the use of satellite cells for cardiac regeneration strategies [144].
Table 8. Clinical trial with satellite cells for cardiac regeneration.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Herreros [143] Phase 1 Non-AMI SI Treated: 12 Yes
Non-AMI: non-acute myocardial infarction; SI: sub-epicardial injection.
Cardiac Stem Cells (CSCs)
The ability of regenerating the heart of some animals, including zebrafish [143] and postnatal
mice [144], together with some reports of a cell turnover of cardiac cellular components [7], suggested
the idea that a population of resident stem cells could be present also in the heart. Indeed, a series of
different stem cell populations have been described in mammals, including humans: c-kit positive
cells (c-kit+) [145], sca-1 positive cells (sca-1+) [146], cardiosphere-derived cells (CDCs) [147], side
population cells [148], isl1 positive cells (isl-1+) [149], and cardiac atrial appendage stem cells
(CASCs) [150]. Actually, c-kit+ cells were the first putative CSCs population identified in the heart,
which showed promising results after transplantation, attenuating ventricular remodeling and
improving cardiac function in mouse and rat models [151,152]. For these reasons, c-kit+ cells were used
in the randomized clinical trial SCIPIO (Stem Cell Infusion in Patients with Ischemic cardiomyopathy),
demonstrating a significant increase in left ventricular ejection fraction after one year of follow up
in patients who received c-kit+ cells injection [153]. However, many independent groups failed to
reproduce these positive results, using c-kit+ cells, raising several still-unanswered questions on the real
contribution of c-kit+ cells in cardiac regeneration and cardiac function recovery [154–156]. Despite
this aspect, another clinical trial with c-kit+ cells is ongoing: indeed, the phase II CONCERT-HF
(Combination of Mesenchymal and c-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart
Failure) trial aims to investigate the potential therapeutic effects of the infusion of c-kit+ cells,
BM-MSCs or the combination of the two populations on patients with myocardial injury [157].
Another cardiac progenitor cell population has been identified using the stem cell antigen-1 (Sca-1),
which is a surface marker of somatic and hematopoietic stem cells. Sca-1+ cells were able to
differentiate in beating cardiomyocytes when treated with 5-azacytidine [146] and were shown to
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reduce ventricular remodeling after transplantation, improving cardiac function by the induction of
angiogenesis [146,158].
A third type of cardiac progenitors are the cardiosphere-derived cells (CDCs), which have
been shown to be clonogenic and have multilineage potential, and that can be safely delivered
via intracoronary injections. They have been shown to mediate scar reduction after myocardial
infarction, to increase the viable myocardium, and to contribute to the improvement of cardiac
function in preclinical models [147]. Recently, CDCs have been used in a clinical trial, CADUCEUS
(CArdiosphere-Derived aUtologous stem Cells to reverse ventricular dysfunction), confirming their
ability to promote cardiac regeneration, reducing the scar size and thickening the wall of the infarcted
zone [159–161] (Table 9).
Finally, cardiac atrial appendage stem cells (CASCs) are the most recent cardiac stem cell
population isolated. These cells are characterized by high activity of the aldehyde dehydrogenase,
and they have shown better cardiomyogenic potential than other CSCs [150]. Preliminary results on
a myocardial infarction model in minipig indicated that CASCs could preserve the cardiac function
through the cardiomyogenic differentiation of implanted cells [162].
Overall, while all these results with CSCs seem quite promising, the real regenerative potential
and, truly, even the existence of some types of CSCs remains controversial, as the reproducibility of
some results reported in the literature is under investigation [156]. Moreover, it seems very unlikely
that so many different stem cell populations reside inside the cardiac tissue, as compared to other
organs, especially considering the poor intrinsic regenerative capacity of the heart itself. At this
stage, further unbiased comparative studies are mandatory to fully understand the role of CSCs in
ameliorating cardiac function after acute or chronic injuries, analyzing the mechanisms responsible for
the reported, yet somehow difficult to be reproduced, beneficial effects.
Table 9. Clinical trials with CSCs for cardiac regeneration.
Reference Clinical Trial Disease Delivery Method Subjects LVEF Improvement
Bolli [145] SCIPIO ICM IC Treated: 16Control: 5 Yes
Makkar [146]
Malliaras [147] CADUCEUS AMI IC
Treated: 17
Control: 8 Yes
Bolli [148] CONCERT-HF ICM IM Treated: 9Control: 9 Not shown
ICM: ischemic cardiomyopathy; IC: intracoronary infusion; AMI: acute myocardial infarction; IM:
intramyocardial injection.
2.2.3. Induced-Pluripotent Stem Cells (iPSCs)
In 2006, Yamanaka and colleagues developed a method for the generation of ESC-like cells
from mouse fibroblasts by the transduction of defined transcription factors (i.e., Oct-3/4, Sox2, Klf4
and c-Myc) through lentiviral vectors [149]. The next year, the same method was used on human
fibroblasts to generate human induced pluripotent stem cells (iPSCs) [150], placing a milestone in
the field of stem cell biology. These cells, similarly to ESCs, can differentiate into derivatives of all
three germ layers both in vitro and in vivo and can form teratomas when implanted in a nude mouse.
The differentiation potential of iPSCs has been extensively employed to generate CMs, although
the efficiency of the differentiation process was lower than with ESCs [151–153]. However, CMs
generated from iPSCs showed a pattern of cardiac gene expressions similar to that of hESC-derived
CMs, including the expression of Nkx2.5, troponin T, α-myosin heavy chain, α-actinin, ANF, myosin
light chain 2 ventricular isoform (MLC2v), and myosin light chain 2 atrial isoform (MLC2a). Moreover,
they exhibit spontaneous contractions, fetal-like ion channel patterns [154], and electrophysiological
signals [155]. In the past decade, a series of alternative protocols have been developed to improve
CMs generation, including the use of bioreactors [156], the application of a two-medium combination
culture protocol [157], the implementation of chemical compounds [158–160], and the reproduction
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of the embryonic heart development by modulating the Wnt/β-catenin pathway [161]. At the same
time, iPSCs also showed a great potential for clinical use, as demonstrated in several animal models.
For example, human iPSCs-derived CMs, cultured on collagen I patches, were able to form grafts with
contractile function in adult rat heart [162]. Moreover, iPSCs restored cardiac function and improved
left ventricular remodeling in porcine and mice models of myocardial infarction [163], promoting
angiogenesis and interstitial networking [164]. To the best of our knowledge, to date, no iPSCs or
iPSC-derived CMs transplantation have been performed on humans, as their use in the clinical practice
is still premature and unsafe. Although there is little doubt about the regenerative potential of iPSCs,
there are still several important limitations that need to be addressed. For example, the efficiency of the
reprogramming process is still quite low, and it greatly (and negatively) influences the time necessary to
generate a sufficient number of CMs for any possible clinical application (generation of 100–1000 CMs
takes at least six months [165]). Moreover, the delivery of the transcription factors used to reprogram
the cells was obtained by retroviruses or lentiviruses infections, and this is known to possibly generate
genetic mutations or the de novo copy number variations inside the cells genome [166,167]. Finally,
iPSCs could have immunogenic properties that could be responsible for adverse immunorejection
after cell transplantation [168]. It is clear that a more accurate evaluation of the genetic and epigenetic
modifications, as well as the determination of the actual immunogenicity of iPSCs are all necessary
before any possible use of these cells in therapeutic strategies.
3. Considerations on Cell Therapy
More than 20 years have passed since the first experiment on cell transplantation for cardiac
regeneration [142] was performed (Table 1). Since then, various clinical trials have been conceived and
started. However, it is difficult to draw conclusions, mainly because most trials are still in the early
phases (I and II), and they can only offer limited, yet essential, information about safety, but only little
insight about the efficacy of the approaches. In fact, they still lack the crucial phase III, which is the
one step that can tell us about the efficacy of the therapy. Indeed, most of the endpoints selected for
the ongoing clinical trials evaluation often have a low therapeutic impact and are not validated and
accepted surrogates for the clinical outcome by the major regulatory agencies, such as the U.S. Food and
Drug Administration [169]. Indeed, left ventricular ejection fraction, maximum oxygen consumption,
brain natriuretic peptide, or myocardial perfusion are not considered hard endpoints, whereas, on
the contrary, primary endpoint of phase III clinical trials should reflect clinically relevant effects, such
as mortality, readmission, reintervention, defibrillator event, left ventricular assist device placement,
or recurrent heart infarct symptoms [170]. Moreover, the majority of cardiac cell-based trials enrolled
patients with acute or convalescent MI, who received prompt and optimal percutaneous reperfusion
therapies to preserve cardiac function, leaving little space for any consistent improvement. This patient
population has low mortality and morbidity, even without any adjunctive cell therapy [169]. A more
detailed and accurate process for patients’ selection based on risk stratification would be helpful
to determine the responsiveness to the therapy. Therefore, it seems clear that more appropriately
targeted trials, in patients with more severe cardiac dysfunction, are needed to establish the real
efficacy of cardiac cell therapy as an effective approach for cardiac regeneration and functional repair.
In particular, there is a need for their standardization in order to allow a useful comparison of the
results and to increase their reproducibility [171].
Beyond these concerns about the selection of the endpoints and patient population, there are also
technical limitations for the procedures that must be faced [172]. For instance, it is important to define
the maturation status of the engrafted cells, because while it has been demonstrated that adult mature
CMs do not survive transplantation [39], partially differentiated cells, such as those derived from ESCs
or MSCs, can cause arrhythmias [59] or tumor formation [173], negatively influencing the outcome
of the intervention. Moreover, and possibly most importantly, there is increasing evidence that most
of the injected cells do not survive after transplantation, because they are either immunologically
rejected, they do not find a proper microenvironment, they are trapped in pulmonary vasculature,
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or they diffuse throughout the entire body with the circulatory system [174]. To partially circumvent
these difficulties, different routes of cell administration have been tested [175], including surgical
intramyocardial injection, catheter-based intramyocardial administration, trans-endocardial injection,
trans-coronary venous injection, intravenous infusion, intracoronary artery administration, retrograde
coronary venous delivery system, and engineered monolayer tissue transplantation. Overall, each
different protocol showed both advantages and disadvantages, and there are no real unbiased and
comprehensive comparative studies, suggesting that it is almost impossible to define a standard
protocol for cell administration [176]. For example, intramyocardial delivery resulted in better cardiac
cell retention and allowed the delivery of a high number of cells. However, this technique is very
invasive, and the cell distribution might be even too localized. In contrast, intracoronary delivery
is simpler than intramyocardial injection, and it enables a homogeneous distribution inside large
myocardial regions. However, cell retention is low and the number of cells that can be delivered
by each infusion is limited [177–179]. Moreover, it is unclear whether the delivered cells can couple
and contract with existing cardiac tissue. In fact, the improvement of cardiac function observed in
the clinical trials could be related to other aspects, including paracrine effects due to the secretion of
soluble factors by transplanted cells that eventually induce different processes, such as myocardial
protection, the activation or amplification of endogenous repair processes, neovascularization, and
cardiac remodeling [180,181]. This hypothesis was confirmed by a series of studies, both in vitro and
in vivo, on the effects of stem cell exosomes’ treatment on cell protection and cardiac regeneration. The
results showed that exosomes increased the apoptosis resistance of cultured cardiomyocytes (Xiao et al.,
2016), and, moreover, it augmented the cardiac function of infarcted hearts in animal models [182–185].
In particular, they induced angiogenesis and cardiomyocyte survival, reducing fibrosis and the left
ventricle remodeling. The promising results suggest that exosomes could represent the first step for
a cell-free therapy for cardiovascular disease, which would be more advantageous than cell therapy,
considering different aspects, such as the costs, the standardization of the therapy, the scale-up of the
production process and the possibility to engineer ad hoc.
In conclusion, cell therapies for cardiac regeneration could be valid approaches that still need
more accurate and extensive studies to determine and improve their feasibility and efficacy. The
long-term therapeutic effects have yet to be monitored in order to determine whether cell therapy has
the potential to increase lifespan, decrease mortality, and to improve patients’ quality of life. Moreover,
as there are some safety issues, especially with the use of more undifferentiated progenitors, a careful
evaluation of the potential side effects of cardiac cell therapy has to be conducted before any clinical
application can be foreseen.
4. Conclusions
Identifying new therapies for heart diseases, which still represent the primary cause of death in
the Western world, is a difficult challenge for modern medicine. As described in this review, in the last
two decades, an impressive number of cell-based clinical trials have been conducted with the same
overall objective of replacing dead (or damaged) cardiomyocytes with functional ones and restoring
the cardiac functionality (Figure 1). However, while the pre-clinical results on animal models generated
high expectations, human trials gave very controversial results. In fact, the extremely heterogeneous
experimental conditions of the trials, including differences in the cell types used, in the doses and the
timings of intervention, in the delivery strategies, in the patients’ selection, and in the time points
evaluated, gave rise to often contradictory results. Furthermore, to date, even the most favorable
approaches showed only modest long-term outcomes. However, these studies and clinical trials
enabled the discovery of critical signaling pathways and transcription-factor networks involved in
heart development and regeneration, including cardiac stem cell differentiation. Moreover, it is now
unequivocally demonstrated that: (a) cell therapy for cardiac regeneration is feasible and generally
safe; (b) the exogenous delivery of adult stem cells suffers from poor engraftment and retention in the
heart; and (c) the positive effects of stem cell approaches for cardiac regeneration are mainly mediated
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by paracrine effects. Therefore, while new cell-based approaches are still under development, many
argue that the delivery of regenerating factors, including small molecules and recombinant proteins,
might be the winning strategy. Clearly, future trials will need to be closely monitored using more
standardized and reliable analytical tools to evaluate the outcomes in order to avoid the previous
chaotic generation of unreproducible data, keeping in mind that the number of cardiac diseases are
increasingly growing, and patients are in urgent need of novel therapies.
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